Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

IPO Watch: Gefen Technologies to list on ASX with digital marketing platform for agents

  • In News
  • June 11, 2021
  • Samantha Freidin
IPO Watch: Gefen Technologies to list on ASX with digital marketing platform for agents

With initial plans to list in the Australian market last year furloughed by the pandemic, Israeli tech company Gefen Technologies is finally joining the dozen Israeli companies on the ASX, having closed their $25 million IPO at the end of last month.

Israel is renowned for their ‘start up culture’, especially in tech, having produced apps like Waze, which was bought by Google for over $1 billion back in 2013.

In line with the tech trend, Gefen is a unique software platform for ‘regulation-heavy industries’ that require agents to sell complex products where human touch, advice and expertise is required.

Currently the main focus is on insurance, financial services and realty with insurance giants TAL, Manulife and Generali Group already amongst their 31 existing clients. The platform allows communication from large companies to the smaller insurance brokers who are selling their products.

The software-as-a-service tech is highly adaptable and could become essential to other industries. The ability for large companies to efficiently distribute their marketing and message to a salesforce, to then sell to customers is critical in an increasingly digital world.

The platform is a scalable solution to streamline processes, with significant growth opportunities. This is primarily due to the large addressable markets within highly regulated and compliance focused sectors. The insurance and financial services sectors have total addressable markets of approximately $358 billion and $462 billion respectively.

Founded in 2014 by former lawyer David Nash, IT systems architect Elad Daniel, and former member of the Israeli air force Orni Daniel, the trio has seen the Company go from strength to strength.

The digitisation of almost all business processes accelerated by the pandemic was the catalyst for their 2020 revenue of $16.4 million, a 264% Compounded Annual Growth Rate on the previous year which yielded $4.5 million.

Since 2016 Gefen has secured over USD $14 million in venture capitalist support, plus a $6.5 million sum from two oversubscribed pre-IPO funding pushes in Australia. The Company piqued the interest of Regal Funds Management and Ellerston Capital who both bought in.

25 million shares will be issued from the IPO at $1 per share. The expected market cap following the offer is $128 million.

Funds raised will primarily be utilised to expand sales and marketing and develop the business further through research and development.

As the world becomes increasingly digital, Gefen Technologies is in a unique position to grow and potentially corner the market becoming an essential player in the agent based sales game.

RM Corporate Finance and Morgans Corporate acted as Joint Lead Managers for the IPO which was not underwritten. Gefen is expected to commence trading on the ASX under the indicative ticker GFN on 17 June 2021.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • elad daniel
  • gefen technologies
  • gfn
  • initial public offer
  • IPO
  • israeli company
  • orni daniel
  • tal
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.